<DOC>
	<DOC>NCT02181322</DOC>
	<brief_summary>Study to assess the effect of food on the pharmacokinetics of meloxicam after a single p.o. administration of 22.5 mg meloxicam oral suspension and to investigate dose-proportionality over a dosage range of 7.5 mg to 22.5 mg</brief_summary>
	<brief_title>Study to Assess the Effect of Food on the Pharmacokinetics of Meloxicam After Single Administration and to Investigate Dose-proportionality Over a Dosage Range</brief_title>
	<detailed_description />
	<mesh_term>Meloxicam</mesh_term>
	<criteria>Healthy male or female subjects as determined by results of screening Age range from 21 to 50 years BrocaIndex + 20% In accordance with Good Clinical Practice (GCP) and the local legislation all volunteers will have given their written informed consent prior to admission to the study Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders Surgery of the gastrointestinal tract (except appendectomy) Disease of the central nervous system (such a epilepsy) or psychiatric disorders or neurological disorders History of orthostatic hypotension, fainting spells or blackouts Chronic or relevant acute infections History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator Intake of drugs with a long halflife (&gt; 24 hours) within at least one month or less than ten halflives of the respective drug before enrolment in the study Use of any drugs which might influence the results of the trial (&lt;= one week prior to administration or during the trial) Participation in another trial with an investigational drug (&lt;= two months prior to administration or during the trial) Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day) Inability to refrain from smoking on trial days Alcohol abuse (&gt; 60 g/day) Drug abuse Blood donation (&gt;= 100 mL within four weeks prior to administration or during the trial Excessive physical activities (within the last week before study) Anl laboratory value outside the reference range of clinical relevance History of haemorrhagic diatheses History of gastrointestinal ulcer, perforation or bleeding History of bronchial asthma For female subjects: Pregnancy Positive pregnancy test No adequate contraception e.g sterilisation, intrauterine pessary, oral contraceptives Inability to maintain this adequate contraception during the whole study period Lactating</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>